Chiara Cremolini

Active 2009–2026

186
Papers
18,177
Citations
65
h-index
165
i10-index

Citations

Citations per year for Chiara Cremolini1996: 1 citations1999: 1 citations2006: 1 citations2007: 1 citations2009: 5 citations2010: 42 citations2011: 48 citations2012: 42 citations2013: 23 citations2014: 38 citations2015: 69 citations2016: 109 citations2017: 183 citations2018: 140 citations2019: 586 citations2020: 693 citations2021: 723 citations2022: 586 citations2023: 658 citations2024: 1,361 citations2025: 883 citations2026: 69 citations1997–1998: no citations, so these years are not shown2000–2005: no citations, so these years are not shown2008: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,268 citing papers, 18.2% of this breakdownChina: 981 citing papers, 14.1% of this breakdownItaly: 767 citing papers, 11% of this breakdownFrance: 350 citing papers, 5% of this breakdownGermany: 334 citing papers, 4.8% of this breakdownUnited Kingdom: 332 citing papers, 4.7% of this breakdownSpain: 305 citing papers, 4.4% of this breakdownJapan: 280 citing papers, 4% of this breakdownNetherlands: 186 citing papers, 2.7% of this breakdownBelgium: 163 citing papers, 2.3% of this breakdownAustralia: 153 citing papers, 2.2% of this breakdownCanada: 138 citing papers, 2% of this breakdown
0%18.2%Other 24.6%

Fields

  • Medicine66.3%
  • Biochemistry, Genetics and Molecular Biology27.2%
  • Immunology and Microbiology2.6%
  • Engineering1%
  • Materials Science0.6%
  • Computer Science0.6%
  • Other1.7%

Topics

  • Colorectal Cancer Treatments and Studies12.7%
  • Cancer Genomics and Diagnostics7.6%
  • Genetic factors in colorectal cancer5.9%
  • Cancer Immunotherapy and Biomarkers5.3%
  • Lung Cancer Treatments and Mutations3.3%
  • Hepatocellular Carcinoma Treatment and Prognosis3.1%
  • Other62.1%

Coauthors

All papers

Open in search
  1. Treatment of Metastatic Colorectal Cancer: ASCO Guideline

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 602

  2. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 342

  3. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 428

  4. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Salvatore Siena, Chiara Cremolini, Maria Giulia Zampino, Elena Élez, Susana R. Keranen, Ramón Salazar, Pilar Alfonso, John H. Strickler, Andrea Cercek, Kimmie Ng, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, David L. Bajor, Tanios Bekaii‐Saab, Olumide B. Gbolahan, Patrick M. Boland, Daniel Berg, Federico Sanchez, Timothy F. Goggins, Federico Sanchez, Howard A. Burris, Johanna C. Bendell, Darryl Outlaw, Isaac Tafur, Ardaman Shergill, Daniel V.T. Catenacci, Jun Gong, Ignacio Garrido‐Laguna, Gene Grant Finley, Benjamin A. Weinberg, Anthony F. Shields, Philip Philip, Anita Turk, Anthony Nguyen, Fadi Braiteh, Vijay Patel, William Harwin, Ian Anderson, Ajay Kundra, Christopher S. Chen, James M. Ford, Madappa N. Kundranda, Danny Nguyen, Suresh Ratnam, Donald Richards, Sujatha Nallapareddy, Sridhar Beeram, Scott McKenney, Spencer H. Shao, Scott McKenney, Spencer H. Shao - The Lancet Oncology 2023 cited by 245

  5. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - British Journal of Cancer 2020 cited by 354

  6. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng - The Lancet 2023 cited by 323

  7. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Erika Martinelli, Nicoletta Pella, Gianluca Masi, Gabriella Fontanini, Luca Boni, Jérôme Galon, Chiara Cremolini - The Lancet Oncology 2022 cited by 270

  8. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Éric Deutsch, Karla A. Lee, Laura A. Bolte, Johannes R. Björk, Rinse K. Weersma, Fabrice Barlési, Lucas Padilha, Ana Finzel, Morten L. Isaksen, Bernard Escudier, Laurence Albigès, David Planchard, Fabrice André, Chiara Cremolini, Stéphanie Martinez, Benjamin Besse, Liping Zhao, Nicola Segata, Jérôme Wojcik, Guido Kroemer, Laurence Zitvogel - Cell 2024 cited by 181

  9. Colorectal cancer

    Authors: , , , , , , , , - The Lancet 2024 cited by 356

  10. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zhen Shi, Sandhya Mandlekar, Mark T. Lin, Stephanie Royer‐Joo, Julie Chang, Tomi Jun, Neekesh V. Dharia, Jennifer L. Schutzman, GO42144 Investigator and Study Group, Sae-Won Han - Nature Medicine 2023 cited by 122

  11. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrea Sartore‐Bianchi, Alberto Bardelli - Nature Medicine 2015 cited by 1,096

  12. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

    Authors: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 cited by 420

  13. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 1,093

  14. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 1,078

  15. Quantitative evidence for early metastatic seeding in colorectal cancer

    Authors: , , , , , , , , , , , , , , - Nature Genetics 2019 cited by 524

  16. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 cited by 185

  17. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 236

  18. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Di Bartolomeo, Filippo de Braud, Filippo Pietrantonio - Journal of Clinical Oncology 2022 cited by 129

  19. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 cited by 111

  20. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Filippo Pietrantonio - Journal for ImmunoTherapy of Cancer 2022 cited by 120

  21. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mario Roselli, Samanta Cupini, Serafina Mammoliti, Elisabetta Fenocchio, E. Corgna, Vittorina Zagonel, Gabriella Fontanini, Clara Ugolini, Luca Boni, Alfredo Falcone, Alfredo Falcone, Sara Lonardi, Filippo de Braud, Roberto Bordonaro, Evaristo Maiello, Emiliano Tamburini, Daniele Santini, Giovanni Luca Frassineti, Teresa Gamucci, Giuseppe Aprile, Alberto Zaniboni, Cristina Granetto, Angela Buonadonna, Francesco Di Costanzo, Gianluca Tomasello, Luca Gianni, Samantha Di Donato, Chiara Carlomagno, Matteo Clavarezza, Patrizia Racca, Andrea Mambrini, Mario Roselli, Giacomo Allegrini, Alberto Sobrero, Massimo Aglietta, E. Corgna, Enrico Cortesi, Domenico Corsi, Alberto Ballestrero, Andrea Bonetti, Francesco Clemente, Enzo Maria Ruggeri, Fortunato Ciardiello, Marco Benasso, S. Vitello, Saverio Cinieri, Stefania Mosconi, Nicola Silvestris, Antonio Frassoldati, S. Cupini, Alessandro Bertolini, Giampaolo Tortora, Carmelo Bengala, Daris Ferrari, Antonia Ardizzoia, Carlo Milandri, Silvana Chiara, Gianpiero Romano, Stefania Miraglia, Laura Scaltriti, Francesca Pucci, Livio Blasi, Silvia Brugnatelli, Luisa Fioretto, Angela Stefania Ribecco, Raffaella Longarini, M. Frisinghelli, Maria Banzi - The Lancet Oncology 2020 cited by 325

  22. Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrea Sartore‐Bianchi, Alberto Bardelli - Nature Medicine 2015 cited by 263

  23. KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis

    Authors: , , , , , , - JNCI Journal of the National Cancer Institute 2021 cited by 114

  24. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 78